GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (TSXV:LOVE) » Definitions » Net Cash per Share

Cannara Biotech (TSXV:LOVE) Net Cash per Share : C$-0.67 (As of Aug. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Cannara Biotech's Net Cash per Share for the quarter that ended in Aug. 2024 was C$-0.67.

The historical rank and industry rank for Cannara Biotech's Net Cash per Share or its related term are showing as below:

During the past 7 years, the highest Price-to-Net-Cash Ratio of Cannara Biotech was 19.38. The lowest was 19.38. And the median was 19.38.

TSXV:LOVE's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.715
* Ranked among companies with meaningful Price-to-Net-Cash only.

Cannara Biotech Net Cash per Share Historical Data

The historical data trend for Cannara Biotech's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Net Cash per Share Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Net Cash per Share
Get a 7-Day Free Trial -0.12 -0.23 -0.53 -0.64 -0.67

Cannara Biotech Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 -0.67 -0.70 -0.68 -0.67

Competitive Comparison of Cannara Biotech's Net Cash per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannara Biotech's Price-to-Net-Cash Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Price-to-Net-Cash falls into.



Cannara Biotech Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Cannara Biotech's Net Cash per Share for the fiscal year that ended in Aug. 2024 is calculated as

Net Cash per Share (A: Aug. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(6.62-66.768-0)/90.019
=-0.67

Cannara Biotech's Net Cash per Share for the quarter that ended in Aug. 2024 is calculated as

Net Cash per Share (Q: Aug. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(6.62-66.768-0)/90.019
=-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannara Biotech  (TSXV:LOVE) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Cannara Biotech Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannara Biotech Business Description

Traded in Other Exchanges
Address
1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
Executives
Nicholas Sosiak Senior Officer
Olymbec Investments Inc. 10% Security Holder
Derek Elan Stern Director
Donald John Olds Director
Scott Carroll Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Zohar Krivorot Director, Senior Officer
Brian Sherman Senior Officer
Avi Krivorot Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Lennie Ryer Senior Officer
Jack M. Kay Director
Donal Carroll Director or Senior Officer of 10% Security Holder